Literature DB >> 1486202

Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses.

S A Fausti1, R H Frey, J A Henry, D J Olson, H I Schaffer.   

Abstract

Subjects receiving treatment with ototoxic agents were evaluated concurrently with conventional and high-frequency (> or = 8 kHz) behavioral threshold measures and with ABR to click and to 8, 10, 12, and 14 kHz tone-burst stimuli. Behavioral threshold data revealed ototoxic change in 51 percent of ears evaluated. Of these ears demonstrating behavioral change, 90 percent revealed concurrent ABR changes. If only ABR monitoring with high-frequency tone-burst stimuli had been used, 87 percent of allears showing behavioral change would have been identified. Three fourths of these would have been identified from wave V responses, with 87 percent identified from the two highest frequencies tested for each individual. This research suggests that behavioral change is reflected accurately in the ABR, that high-frequency tone bursts will identify a majority of initial ototoxic changes, and that monitoring hearing with high-frequency, tone-burst-evoked ABRs during treatment with potentially ototoxic agents is significantly more effective than click-evoked ABRs for early detection of ototoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486202

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  13 in total

1.  Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.

Authors:  Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney
Journal:  Ear Hear       Date:  2018 Jan/Feb       Impact factor: 3.570

Review 2.  New developments in aminoglycoside therapy and ototoxicity.

Authors:  Jing Xie; Andra E Talaska; Jochen Schacht
Journal:  Hear Res       Date:  2011-05-27       Impact factor: 3.208

Review 3.  New treatment options for hearing loss.

Authors:  Ulrich Müller; Peter G Barr-Gillespie
Journal:  Nat Rev Drug Discov       Date:  2015-03-20       Impact factor: 84.694

4.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

5.  Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett McMillan; Wendy J Helt; Marilyn Dille
Journal:  J Rehabil Res Dev       Date:  2014

Review 6.  Clinical measures of auditory function: the cochlea and beyond.

Authors:  Rachael R Baiduc; Gayla L Poling; OiSaeng Hong; Sumitrajit Dhar
Journal:  Dis Mon       Date:  2013-04       Impact factor: 3.800

7.  ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.

Authors:  Marilyn F Dille; Roger M Ellingson; Garnett P McMillan; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2013-10       Impact factor: 1.664

8.  Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.

Authors:  Guiscardo Lorito; Stavros Hatzopoulos; Göran Laurell; Kathleen C M Campbell; Joseph Petruccelli; Pietro Giordano; Krzysztof Kochanek; Lech Sliwa; Alessandro Martini; Henryk Skarzynski
Journal:  Med Sci Monit       Date:  2011-08

9.  Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.

Authors:  Chawangwa Modongo; Rafal S Sobota; Boikobo Kesenogile; Ronald Ncube; Giorgio Sirugo; Scott M Williams; Nicola M Zetola
Journal:  BMC Infect Dis       Date:  2014-10-09       Impact factor: 3.090

10.  Study of streptomycin-induced ototoxicity: protocol for a longitudinal study.

Authors:  Adebolajo A Adeyemo; Odunayo Oluwatosin; Olayemi O Omotade
Journal:  Springerplus       Date:  2016-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.